Suloctidil was a sulfer-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator. In 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity. Suloctidil more potently inhibited calcium-induced contractions in small arteries (mesenteric and saphenous artery), than in the aorta. Suloctidil also reduced the tonic component of the responses to norepinephrine. In contrast to the effects on calcium-induced contractions, the effects of suloctidil on norepinephrine-induced responses was mainly noncompetitive. References: Chauvet-Monges AM, Faure R, Crevat A. 1H-NMR study of suloctidil-A23187 calcium ionophore interaction. Chem Biol Interact. 1993 Feb;86(2):163-9. PubMed PMID: 8383582.

纯度：≥98%

CAS：54767-75-8